BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members

Molecular Cancer Therapeutics

Volumn 15, Issue 9, 2016, Pages 2030-2041

  Hogg, Simon J ^a,b   Newbold, Andrea ^a   Vervoort, Stephin J ^a   Cluse, Leonie A ^a   Martin, Benjamin P ^a   Gregory, Gareth P ^a,b,c   Lefebure, Marcus ^a,b   Vidacs, Eva ^a   Tothill, Richard W ^a   Bradner, James E ^d   Shortt, Jake ^a,b,c,e   Johnstone, Ricky W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SOUTHERN HEALTH   (Australia)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; APABETALONE; BET PROTEIN; BIM PROTEIN; BIRABRESIB; BROMODOMAIN INHIBITOR; DOXORUBICIN; ETOPOSIDE; FEDRATINIB; MESSENGER RNA; MYC PROTEIN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; RAS PROTEIN; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; PROTEIN P21; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER RESISTANCE; CONTROLLED STUDY; CYTOSTASIS; DISEASE COURSE; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MORTALITY; MULTIGENE FAMILY; ONCOGENE MYC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AZEPINES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; MICE; MULTIGENE FAMILY; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990935124     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0924     Document Type: Article

References (42)

1. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell-cycle progression. Mol Cell Biol 2008;28:967-76.
2. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
3. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013;24:777-90.
4. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
5. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
6. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012;120:2843-52.
7. Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 2015;21:113-22.
8. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
9. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan W-I, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
10. Wyce A, Ganji G, Smitheman KN, Chung C-W, Korenchuk S, Bai Y, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 2013;8:e72967.
11. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood 2015;126:1565-74.
12. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, et al. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLTITD. Mol Cancer Ther 2014;13:2315-27.
13. Huang B, Yang X-D, Zhou M-M, Ozato K, Chen L-F. Brd4 coactivates transcriptional activation of NF-kB via specific binding to acetylated RelA. Mol Cell Biol 2009;29:1375-87.
14. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
15. Adams J, Harris A, Pinkert C, Corcoran L, Alexander W, Cory S, et al. The cmyc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1984;318:533-8.
16. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. ProcNatl Acad SciUS A 2014;111:E2721-E30.
17. Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013;121:2964-74.
18. Lindemann R, Newbold A, Whitecross K, Cluse L, Frew A, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007;104:8071-6.
19. Essmann F, Engels IH, Totzke G, Schulze-Osthoff K, Jänicke RU. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell-cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 2004;64:7065-72.
20. Li J, Doyle MA, Saeed I, Wong SQ, Mar. V, Goode DL, et al. Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment. PLoS ONE 2014;9:e95217.
21. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 1997;337:529-34.
22. Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks K-M, et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 2011;71:3603-15.
23. Poortinga G, Wall M, Sanij E, Siwicki K, Ellul J, Brown D, et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res 2011;39:3267-81.
24. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary P. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 2014;33:2928-37.
25. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
26. Patel AJ, Liao C-P, Chen Z, Liu C, Wang Y, Le LQ. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through bim induction. Cell Reports 2014;6:81-92.
27. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, et al. Evasion of the p53 tumour surveillance network by tumourderived MYC mutants. Nature 2005;436:807-11.
28. Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia 2015;29:1437-41.
29. Fong C, Gilan O, Lam E, Rubin A, Ftouni S, Tyler D, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 2015;525:538-42.
30. Rathert P, Roth M, Neumann T, Muerdter F, Roe J-S, Muhar M, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 2015;525:543-7.
31. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014;10:305-12.
32. Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harbor Perspect Biol 2012;4:a009829.
33. Mead G, Sydes M, Walewski J, Grigg A, Hatton C, Norbert P, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264-74.
34. Chng W, Huang G, Chung T, Ng S, Gonzalez-Paz N, Troska-Price T, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011;25:1026-35.
35. Testoni M, Kwee I, Greiner TC, MontesMoreno S, Vose J, Chan WC, et al. Gains of MYC locus and outcome in patients with diffuse large Bcell lymphoma treated with RCHOP. Br J Haematol 2011;155:274-7.
36. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9.
37. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013;121:4021-31.
38. Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, et al. Blockade of oncogenic IkB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014;111:11365-70.
39. Emadali A, Rousseaux S, BruderCosta J, Rome C, Duley S, Hamaidia S, et al. Identification of a novel BET bromodomain inhibitorsensitive, gene regulatory circuit that controls rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med 2013;5:1180-95.
40. Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in tripe-negative breast cancer. Nature 2016;529:413-17.
41. Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leuk Lymphoma 2015;56:2146-52.
42. Tan Y, Sementino E, Pei J, Kadariya Y, Ito TK, Testa JR. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biol Ther 2015;16:580-8.